(Reuters) – Eli Lilly and Co (LLY.N) said on Monday it would buy Loxo Oncology Inc (LOXO.O) for about $8 billion in cash, making its biggest bet on a cancer therapy market expected to be worth several billions of dollars.
FILE PHOTO: An orchid stands on a table at the entrance to Loxo Oncology headquarters in Stamford, Connecticut, U.S., February 20, 2018. Picture taken February 20, 2018. REUTERS/Bill Berkrot
The deal follows Bristol-Myers Squibb Co (BMY.N) agreement last week to buy Celgene Corp (CELG.O) for $74 billion, and gives Lilly access to Loxo’s portfolio of targeted medicines that treat cancers caused by rare gene mutations.
The portfolio is centered around the company’s first commercial medicine, Vitrakvi, which is sold in partnership with Bayer AG (BAYGn.DE).
Shares of Lilly were down 2.5 percent while those of Loxo were trading close the offer price of $235 per share, which was at a 68 percent premium to the stock’s Friday close.
“The acquisition of Loxo, along with last weeks acquisition of Celgene, may represent the cream of the crop in biotech being harvested by big pharma,” IFS Securities analyst David Bouchey said.
“The size of the deal may indicate Lily’s willingness to pay up to out-bid the competition.”
But BMO Capital Markets analyst Alex Arfaei said the $8 billion valuation seemed high as Loxo was not profitable yet and Wall Street expects revenue of $1 billion only by 2023.
The company bought Armo Biosciences Inc, a developer of drugs that help the body’s immune system to fight cancer, for $1.6 billion last year and indicated that it was on the lookout for similar acquisitions.
Indianapolis, Indiana-based Lilly’s oncology portfolio includes lung cancer drug Alimta, Erbitux, a treatment for certain types of colorectal cancers and gastric cancer medicine Cyramza. Alimta brought in $520.5 million in the latest reported quarter.
Loxo’s Vitrakvi, priced at $32,800 per month, could eventually generate over $750 million in sales along with another similar drug, LOXO-195, according to brokerage Piper Jaffray & Co.
Loxo is also developing a drug that targets a rare gene fusion mutation known as RET, seen in thyroid, lung and other cancers.
Lilly’s offer of $235 per share in cash represents a premium of about 68 percent to Loxo’s Friday close. Loxo’s shares jumped to $230 before the bell, while those of Lilly dropped 2.7 percent to $111.60.
Loxo’s shares have run up nearly 65 percent over the past 12 months, while Lilly’s stock has surged 34 percent in the same time.
The deal was announced just ahead of the start of the annual JPMorgan healthcare conference in San Francisco, scheduled to begin on Monday morning.
Reporting by Ankur Banerjee and Tamara Mathias in Bengaluru; Editing by Saumyadeb Chakrabarty and Sweta Singh